Home > Publications database > Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma. > print

001     287681
005     20240301145119.0
024 7 _ |2 doi
|a 10.1073/pnas.2310479121
024 7 _ |2 pmid
|a pmid:38335255
024 7 _ |2 ISSN
|a 0027-8424
024 7 _ |2 ISSN
|a 1091-6490
024 7 _ |2 altmetric
|a altmetric:159516164
037 _ _ |a DKFZ-2024-00309
041 _ _ |a English
082 _ _ |a 500
100 1 _ |0 0000-0002-9406-6478
|a Sainero-Alcolado, Lourdes
|b 0
245 _ _ |a Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma.
260 _ _ |a Washington, DC
|b National Acad. of Sciences
|c 2024
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1707726528_28232
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Metabolic reprogramming is critical during clear cell renal cell carcinoma (ccRCC) tumorigenesis, manifested by accumulation of lipid droplets (LDs), organelles that have emerged as new hallmarks of cancer. Yet, regulation of their biogenesis is still poorly understood. Here, we demonstrate that MYC inhibition in ccRCC cells lacking the von Hippel Lindau (VHL) gene leads to increased triglyceride content potentiating LD formation in a glutamine-dependent manner. Importantly, the concurrent inhibition of MYC signaling and glutamine metabolism prevented LD accumulation and reduced tumor burden in vivo. Furthermore, we identified the hypoxia-inducible lipid droplet-associated protein (HILPDA) as the key driver for induction of MYC-driven LD accumulation and demonstrated that conversely, proliferation, LD formation, and tumor growth are impaired upon its downregulation. Finally, analysis of ccRCC tissue as well as healthy renal control samples postulated HILPDA as a specific ccRCC biomarker. Together, these results provide an attractive approach for development of alternative therapeutic interventions for the treatment of this type of renal cancer.
536 _ _ |0 G:(DE-HGF)POF4-311
|a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |2 Other
|a HILPDA
650 _ 7 |2 Other
|a MYC
650 _ 7 |2 Other
|a clear cell renal cell carcinoma
650 _ 7 |2 Other
|a glutamine
650 _ 7 |2 Other
|a lipid droplets
700 1 _ |0 0009-0001-5321-1253
|a Garde-Lapido, Elisa
|b 1
700 1 _ |0 P:(DE-He78)7b7131e0870c28d432e48873d295460f
|a Snaebjörnsson, Marteinn Thor
|b 2
|u dkfz
700 1 _ |a Schoch, Sarah
|b 3
700 1 _ |0 0000-0003-3823-1499
|a Stevens, Irene
|b 4
700 1 _ |a Ruiz-Pérez, María Victoria
|b 5
700 1 _ |0 0000-0003-4647-9769
|a Dyrager, Christine
|b 6
700 1 _ |a Pelechano, Vicent
|b 7
700 1 _ |0 0000-0002-7749-5043
|a Axelson, Håkan
|b 8
700 1 _ |0 P:(DE-He78)94ae391f53fb9285e1b68f9930615af1
|a Schulze, Almut
|b 9
|u dkfz
700 1 _ |0 0000-0001-6376-7792
|a Arsenian-Henriksson, Marie
|b 10
773 _ _ |0 PERI:(DE-600)1461794-8
|a 10.1073/pnas.2310479121
|g Vol. 121, no. 7, p. e2310479121
|n 7
|p e2310479121
|t Proceedings of the National Academy of Sciences of the United States of America
|v 121
|x 0027-8424
|y 2024
909 C O |o oai:inrepo02.dkfz.de:287681
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)7b7131e0870c28d432e48873d295460f
|a Deutsches Krebsforschungszentrum
|b 2
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)94ae391f53fb9285e1b68f9930615af1
|a Deutsches Krebsforschungszentrum
|b 9
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF4-311
|1 G:(DE-HGF)POF4-310
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Krebsforschung
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 _ _ |0 StatID:(DE-HGF)0430
|2 StatID
|a National-Konsortium
|d 2023-08-26
|w ger
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b P NATL ACAD SCI USA : 2022
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)1060
|2 StatID
|a DBCoverage
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)1040
|2 StatID
|a DBCoverage
|b Zoological Record
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)9910
|2 StatID
|a IF >= 10
|b P NATL ACAD SCI USA : 2022
|d 2023-08-26
920 1 _ |0 I:(DE-He78)A410-20160331
|k A410
|l Metabolismus und Microenvironment
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A410-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21